

Lung Committee

Leadership

Chair: Jhanelle Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Mary Redman, PhD
 Yingqi Zhao, PhD
 Katherine Minichiello, MS
 Jieling Miao, MS
 James Moon, MS
 Lu Qian, MS

Scientific Leadership

Translational Medicine:
 Biology/Pathology: Philip C. Mack, PhD
 Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging: Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology: Roy H. Decker, MD, PhD
 Surgery: Wayne L. Hofstetter, MD
 Subcommittee Chairs:
 Early Stage Disease: Wayne L. Hofstetter, MD
 Raymond Osarogiagbon, MD
 Locally Advanced Disease: Roy H. Decker, MD, PhD
 Shirish Gadgeel, MD (Early Therapeutics)
 Metastatic Disease: Ross Camidge, MD
 Karen Reckamp, MD
 Community Engagement: Paul J. Hesketh, MD
 Suzanne Cole, MD

Designates

Cancer Control Liaison: Gary E. Goodman, MD
 Veterans Affairs: Chao H. Huang, MD
 Cheryl M. Czerlanis, MD
 Data Coordinators: Leah Everhart
 Louise Highleyman
 Larry Kaye
 Amy Johnson
 Clinical Research Project Manager: TBD
 Oncology Research Professionals:
 CRAs: Courtney L. Williamson
 Ginny M. Keeling, MS
 Nurses: Kimberly M. Belzer, MS, PAC
 Rosalie Zablocki, RN
 Patient Advocate: Judy Johnson, MBA
 Pharmaceutical Science: Joyce Lee, PharmD
 Kimberly McConnell, PharmD

Protocol Project Managers: Mariah Norman
 Laura Gildner, MS (Lung-MAP)
 Jennifer Beeler (Lung-MAP)
 Clinical Trials Program Manager: Crystal Miwa

Time/Location

Saturday, April 9, 2022 8:30 - 11:30 am
 Room: Columbia A, Level 3

Agenda

8:30 – 8:40 am	General Update
8:40 – 8:50 am	Patient Advocate Update: Judy Johnson, MBA
8:50 – 9:00 am	Thoracic Surgery Session: Wayne Hofstetter, MD
9:00 – 9:10 am	Thoracic Radiation Session: Megan Daly, MD
9:10 – 9:20 am	Translational Medicine Session: Phil C. Mack, PhD
9:20 – 9:30 am	Community Engagement Core: Paul J. Hesketh, MD
9:30 – 10:00 am	Scientific Presentation #1 Targeting myeloid lineage cells to improve ICB efficacy in NSCLC McGarry Houghton, MD Lung SPORE PI Professor, Clinical Research Division & Human Biology Division Fred Hutchinson Cancer Research Center
10:00 – 11:00 am	Thoracic Medical Oncology Session: Jhanelle Gray, MD
11:00 – 11:30 am	Scientific presentation #2 Immuno-oncology Biomarkers on Lung Cancer and the CIMAC-CIDC Network Ignacio I. Wistuba, MD Head ad <i>interim</i> , Division of Pathology and Laboratory Medicine Chair, Department of Translational Molecular Pathology The University of Texas MD Anderson Cancer Center

Active Studies

LUNGMAP, “A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study).” Drs. Herbst, Patel, Gandara, et al. Activation: 1/28/19.

S1800D, “A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small

Lung Committee

Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)." Drs. Padda and Gerber. Activation: 4/2/21.

S1701, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20.

S1929, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20.

S1933, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

S1934, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial Of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22.

CTSU/EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of First-line Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19.

CTSU/A081105, "Randomized Study of Erlotinib Vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Kelly. Activation: 8/18/14; Temporary closure: 6/15/20; Reactivation: 7/15/20. Closed to Accrual: 1/20/21.

CTSU/A081801, "Integration of Immunotherapy into Adjuvant Therapy for

Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20; Temporary closure: 10/22/21.

CTSU/A082002, "A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or without SBRT for PD-L1-Negative, Advanced Non-small Cell Lung Cancer." Dr. Armini. Activation: 12/21/21.

CTSU/A151216, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)." Dr. Gandara. Activation: 8/18/14.

CTSU/E4512, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14.

CTSU/EA5181, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20.

CTSU/NRG-CC003, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20.

CTSU/NRG-LU002, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21.

CTSU/NRG-LU005, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19.

Closed Studies

None since October 2021.

NCI-Approved Concepts

S1900F, "A Phase II Study of Selpercatinib, Carboplatin and Pemetrexed In Patients With RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Elamin and Gray.

Concepts in Development

S1900G, "A Randomized Phase II Study of Capmatinib plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge.

S1900H, "A Phase II Study of Tepotinib and Ramucirumab in Participants with Met Exon 14 Skipping and Advanced Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le.

Lung Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

	LUNGMAP	S1701	S1800A	S1827	S1900A	S1900B	S1900C	S1900E	S1914	S1929	S1933	A081105
Ascension Prov Hospitals - Southfield	12	-	-	-	-	-	-	-	-	1	-	-
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson CC	-	-	-	-	-	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	-	-	-	-	-	-	-	-	-	-	-	-
Baptist Mem HC/Mid South MU NCORP	34	-	-	-	3	-	1	1	2	2	-	-
Boston Med Ctr	-	-	-	3	-	-	-	-	-	-	-	-
CWRU Case CCC LAPS	5	-	-	-	-	-	1	1	-	-	-	6
Ca Res Consortium West Mich NCORP	3	-	1	-	1	-	1	-	2	-	-	-
Ca Res for the Ozarks NCORP	27	-	-	-	-	-	2	-	-	2	3	1
Ca Res of Wisconsin & N Mich Consort	18	-	-	-	2	-	2	3	-	-	-	-
Carle CC NCORP	2	-	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Med Ctr	2	-	-	-	-	-	-	-	-	-	-	-
City of Hope CCC	5	1	-	1	-	-	-	-	-	-	-	1
Columbia U MU NCORP	6	-	-	-	1	-	1	-	-	-	-	-
Columbus NCORP	21	-	-	2	4	-	-	-	-	-	-	-
CommonSpirit Health Research Inst	43	-	6	-	1	-	1	-	1	2	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	1	-	-	-	-	-	-	-	-	-
Dayton NCORP	6	-	-	-	-	-	-	-	-	1	-	-
Essentia Health NCORP	15	-	-	-	-	-	1	-	1	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	4	-	-	-	-	-	-	-	-	-	-	1
Georgia Cares MU NCORP	6	-	1	1	-	-	-	-	2	3	1	-
Georgia NCORP	45	-	3	2	2	-	-	-	1	-	-	-
Gulf South MU NCORP	7	-	-	1	-	-	-	-	1	-	-	-
Hawaii MU NCORP	21	-	1	-	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	102	-	11	-	6	1	1	4	13	10	1	-
Henry Ford Hospital	7	-	-	-	2	-	-	-	-	1	-	2
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	-	-	2
Kaiser Permanente NCORP	51	-	2	-	-	-	1	6	1	-	-	19
Lahey Hospital & Med Ctr	25	-	4	-	-	-	-	-	1	1	2	-
Loma Linda U Med Ctr	5	-	-	-	-	-	1	-	-	-	-	3
Loyola U Med Ctr	18	-	1	-	-	-	-	-	-	-	-	-
Massachusetts Veterans ERIC	28	-	4	-	1	-	-	-	-	-	-	1
Medical U South Carolina MU NCORP	7	-	-	-	-	-	-	1	-	-	-	-
Michigan Ca Res Consortium NCORP	84	-	10	-	3	-	5	4	1	1	-	-
Moffitt CC	5	2	-	1	-	-	-	-	-	-	-	3
Montana Cancer Consortium NCORP	24	-	5	-	2	-	1	-	-	3	1	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	6	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	15	-	1	-	-	-	-	1	-	-	-	-
Nevada Ca Res Foundation NCORP	11	-	1	-	-	-	-	-	-	-	-	-

Lung Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

	LUNGMAP	S1701	S1800A	S1827	S1900A	S1900B	S1900C	S1900E	S1914	S1929	S1933	A081105
New Mexico MU NCORP	64	-	3	1	2	-	-	-	3	3	1	-
Northwell Health NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Northwestern U LAPS	19	1	-	-	-	-	-	-	-	1	-	-
Oregon Health & Science U	1	-	-	-	-	-	-	-	1	-	-	1
Pacific Ca Res Consortium NCORP	12	-	-	-	-	-	-	-	-	3	-	-
SCL Health Saint Joseph Hospital	1	-	-	-	-	-	-	-	1	-	-	-
Salem Hospital	3	-	1	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	43	-	8	4	2	-	-	-	2	3	-	-
Sutter Ca Res Consortium	20	-	2	-	-	-	-	1	-	-	-	1
Don & Sybil Harrington CC	6	-	-	-	-	-	-	-	-	-	-	-
James Graham Brown CC at U Louisville	-	-	-	-	-	-	-	-	-	-	-	-
UC Davis CCC LAPS	20	3	3	1	3	-	-	-	4	1	-	4
UC Irvine Health/Chao Family CCC	17	-	1	1	-	-	-	-	1	-	-	2
UC San Diego Moores CC	9	-	-	-	-	-	-	1	-	-	-	1
UPMC Hillman CC LAPS	13	-	-	-	-	-	-	3	-	-	-	-
USC Norris CCC LAPS	-	-	-	-	-	-	-	-	1	-	-	1
U Arkansas for Medical Sciences	9	-	3	-	-	-	-	-	4	-	-	-
U Cincinnati CC-UC Med Ctr	-	-	-	-	-	-	-	-	-	-	-	1
U Colorado CC LAPS	10	-	1	1	-	-	-	-	2	1	-	9
U Kansas CC - MCA Rural MU NCORP	72	-	4	-	4	-	2	1	-	-	-	1
U Kentucky/Markey CC	40	-	2	1	-	-	3	-	-	-	-	1
U Michigan CCC LAPS	1	-	-	-	-	-	-	-	-	-	-	1
U Mississippi Med Ctr	1	-	1	-	-	-	-	-	-	-	-	2
U Oklahoma Health Sciences Ctr LAPS	24	-	2	1	1	-	-	-	-	-	7	-
U Rochester LAPS	49	-	2	-	3	-	-	5	1	-	-	-
U Texas HSC at San Antonio	-	-	-	-	-	-	-	-	-	-	-	-
U Texas MD Anderson CC LAPS	3	4	-	-	-	-	-	-	-	2	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	-	1	-	-	-	-	2	-	-	-
Upstate Carolina Consortium NCORP	23	-	5	-	-	-	1	-	1	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	-	-	-	-	-
Western States Ca Res NCORP	2	-	-	-	-	-	-	-	-	-	-	-
William Beaumont Hosp-Royal Oak	-	-	-	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	34	-	1	-	1	-	1	-	2	-	-	-
Yale U - Yale CC LAPS	16	-	7	1	1	-	3	-	-	-	-	3
ALLIANCE	562	3	36	9	9	1	9	6	4	3	1	-
CCTG	-	-	-	2	-	-	-	-	-	-	-	-
ECOG-ACRIN	270	2	17	2	5	2	7	8	4	5	-	-
NRG	265	-	15	34	5	2	2	2	6	5	1	-
Total	2,275	16	166	70	64	6	47	48	71	54	18	67

Lung Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

	A081801	A151216	E4512	EA5163	EA5181	EA5182	EA5191	NRGCC003	NRGLU002	NRGLU005	R1308
Ascension Prov Hospitals - Southfield	-	14	1	2	1	-	1	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson CC	1	1	-	-	-	-	-	-	-	1	-
Banner U Med Ctr - Tucson	-	7	2	-	4	-	-	-	-	-	-
Baptist Mem HC/Mid South MU NCORP	-	19	-	-	-	-	-	-	1	3	-
Boston Med Ctr	-	3	-	-	1	-	-	-	-	-	-
CWRU Case CCC LAPS	4	48	-	7	10	-	-	-	-	-	-
Ca Res Consortium West Mich NCORP	-	1	-	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	-	1	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin & N Mich Consort	-	-	-	-	-	-	-	-	-	-	-
Carle CC NCORP	-	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Med Ctr	-	-	-	-	-	-	-	-	-	-	-
City of Hope CCC	-	4	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Columbus NCORP	-	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Inst	-	2	-	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	3	-	-	-	-	-	-	-	-	-
Dayton NCORP	-	8	-	-	-	-	-	-	-	-	-
Essentia Health NCORP	-	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	-	15	-	-	-	-	-	-	-	-	-
Georgia Cares MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Georgia NCORP	-	9	-	1	-	-	-	-	-	-	-
Gulf South MU NCORP	-	-	-	3	-	-	-	-	-	-	-
Hawaii MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	-	-	-	-	-	-	-	1	-	-	-
Henry Ford Hospital	2	29	-	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	8	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	1	197	4	3	-	1	-	-	-	-	-
Lahey Hospital & Med Ctr	-	30	-	1	-	-	-	-	-	-	-
Loma Linda U Med Ctr	-	9	-	-	-	-	-	-	-	-	1
Loyola U Med Ctr	-	21	-	-	2	-	-	-	-	-	-
Massachusetts Veterans ERIC	6	25	-	3	-	-	-	-	-	-	-
Medical U South Carolina MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Michigan Ca Res Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Moffitt CC	5	83	1	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	1	-	-	-	-	1	-
NCORP Carolinas (Prisma Hlth NCORP)	-	1	-	-	-	-	-	-	-	-	-
Nevada Ca Res Foundation NCORP	-	-	-	-	-	-	-	-	-	-	-

Lung Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

	A081801	A151216	E4512	EA5163	EA5181	EA5182	EA5191	NRGCC003	NRGLU002	NRGLU005	R1308
New Mexico MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	1	1	-	-	-	-	-	-	-	-	-
Northwestern U LAPS	-	-	-	-	-	-	-	-	-	-	-
Oregon Health & Science U	4	19	-	-	-	-	-	-	-	-	-
Pacific Ca Res Consortium NCORP	-	4	-	-	-	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	1	2	-	-	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-	-	-	-
Sutter Ca Res Consortium	-	10	-	-	2	-	-	-	-	-	-
Don & Sybil Harrington CC	-	-	-	-	-	-	-	-	-	-	-
James Graham Brown CC at U Louisville	-	5	-	-	-	-	-	-	-	-	-
UC Davis CCC LAPS	-	41	1	6	-	1	-	-	-	-	-
UC Irvine Health/Chao Family CCC	-	12	-	-	-	-	-	-	-	-	-
UC San Diego Moores CC	-	5	-	-	-	-	-	-	-	-	-
UPMC Hillman CC LAPS	-	-	-	-	-	-	-	-	-	-	-
USC Norris CCC LAPS	-	12	-	-	-	-	-	-	-	-	-
U Arkansas for Medical Sciences	-	2	-	1	-	-	-	-	-	-	-
U Cincinnati CC-UC Med Ctr	-	22	1	-	-	-	-	-	-	-	-
U Colorado CC LAPS	3	58	2	-	-	-	1	-	-	1	-
U Kansas CC - MCA Rural MU NCORP	-	28	-	3	-	-	-	-	-	2	-
U Kentucky/Markey CC	-	5	-	-	-	-	-	-	-	-	-
U Michigan CCC LAPS	-	62	-	-	-	-	-	-	-	-	-
U Mississippi Med Ctr	-	26	-	-	-	-	-	-	-	-	-
U Oklahoma Health Sciences Ctr LAPS	-	-	-	-	-	-	-	-	-	-	-
U Rochester LAPS	-	-	-	2	9	-	-	4	-	1	-
U Texas HSC at San Antonio	-	-	-	2	-	-	-	-	-	-	-
U Texas MD Anderson CC LAPS	-	2	1	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	-	1	-	-	-	-	-	-	-
Upstate Carolina Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	1	-	-	-	-	-	-	1	-	-
Western States Ca Res NCORP	-	1	-	-	-	-	-	-	-	-	-
William Beaumont Hosp-Royal Oak	-	2	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	-	-	-	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	3	51	4	10	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-
Total	31	909	17	45	30	2	2	5	2	9	1